Skip to main content
. 2022 Sep 21;10(10):2346. doi: 10.3390/biomedicines10102346

Figure 2.

Figure 2

Study workflow for the discovery and validation of biomarkers representative of antibody-mediated rejection. LC-MS/MS, label-free liquid chromatography-mass spectrometry; ABMR, antibody-mediated rejection; TCMR, T-cell-mediated rejection; NOMOA, no major abnormality; BKVN, BK virus nephropathy; FC, fold change. WB, Western blot analysis; IHC, Immunohistochemistry; ELISA, Enzyme linked immunosorbent assay; LBP, lipopolysaccharide-binding protein; CST3, Cystatin-C; KEGG, GO, Gene Ontology; Kyoto Encyclopedia of Genes and Genomes.